125 related articles for article (PubMed ID: 38396317)
1. Physiologically Based Pharmacokinetic Absorption Model for Pexidartinib to Evaluate the Impact of Meal Contents and Intake Timing on Drug Exposure.
Nakayama S; Lukacova V; Tanabe S; Watanabe A; Mullin J; Suarez-Sharp S; Shimizu T
Clin Pharmacol Drug Dev; 2024 Apr; 13(4):440-448. PubMed ID: 38396317
[TBL] [Abstract][Full Text] [Related]
2. Supporting patients in the transition to the revised pexidartinib dosing regimen: perspectives from the multidisciplinary clinical and allied health professional team.
McCabe C; Wright H; Polson K; Wagner AJ
Orphanet J Rare Dis; 2023 Oct; 18(1):313. PubMed ID: 37805596
[TBL] [Abstract][Full Text] [Related]
3. Dosing Recommendation Based on the Effects of Different Meal Types on Pexidartinib Pharmacokinetics in Healthy Subjects: Implementation of Model-informed Drug Development Strategy.
Zahir H; Yin O; Hsu C; Wagner AJ; Jiang J; Wang X; Greenberg J; Shuster DE; Kakkar T; LaCreta F
Clin Pharmacol Drug Dev; 2023 May; 12(5):475-483. PubMed ID: 36942508
[TBL] [Abstract][Full Text] [Related]
4. Population Pharmacokinetic Analysis of Pexidartinib in Healthy Subjects and Patients With Tenosynovial Giant Cell Tumor or Other Solid Tumors.
Yin O; Wagner AJ; Kang J; Knebel W; Zahir H; van de Sande M; Tap WD; Gelderblom H; Healey JH; Shuster D; Stacchiotti S
J Clin Pharmacol; 2021 Apr; 61(4):480-492. PubMed ID: 33043474
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Absorption and Metabolism-Based DDI Potential of Pexidartinib in Healthy Subjects.
Zahir H; Greenberg J; Shuster D; Hsu C; Watanabe K; LaCreta F
Clin Pharmacokinet; 2022 Nov; 61(11):1623-1639. PubMed ID: 36264536
[TBL] [Abstract][Full Text] [Related]
6. Pexidartinib Long-Term Hepatic Safety Profile in Patients with Tenosynovial Giant Cell Tumors.
Lewis JH; Gelderblom H; van de Sande M; Stacchiotti S; Healey JH; Tap WD; Wagner AJ; Pousa AL; Druta M; Lin CC; Baba HA; Choi Y; Wang Q; Shuster DE; Bauer S
Oncologist; 2021 May; 26(5):e863-e873. PubMed ID: 33289960
[TBL] [Abstract][Full Text] [Related]
7. Real-World Patient Experience of Pexidartinib for Tenosynovial Giant-Cell Tumor.
Lin F; Jacqueline Kwong W; Pan I; Ye X; Dai D; Tap W
Oncologist; 2024 Apr; 29(4):e535-e543. PubMed ID: 37874926
[TBL] [Abstract][Full Text] [Related]
8. Prospects of Treating Tenosynovial Giant Cell Tumor through Pexidartinib: A Review.
Alsayadi YMMA; Chawla PA
Anticancer Agents Med Chem; 2021; 21(12):1510-1519. PubMed ID: 33143617
[TBL] [Abstract][Full Text] [Related]
9. A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors.
Lee JH; Chen TW; Hsu CH; Yen YH; Yang JC; Cheng AL; Sasaki SI; Chiu LL; Sugihara M; Ishizuka T; Oguma T; Tajima N; Lin CC
Invest New Drugs; 2020 Feb; 38(1):99-110. PubMed ID: 30825104
[TBL] [Abstract][Full Text] [Related]
10. Pexidartinib (TURALIO™): The First FDA-Indicated Systemic Treatment for Tenosynovial Giant Cell Tumor.
Monestime S; Lazaridis D
Drugs R D; 2020 Sep; 20(3):189-195. PubMed ID: 32617868
[TBL] [Abstract][Full Text] [Related]
11. ENLIVEN study: Pexidartinib for tenosynovial giant cell tumor (TGCT).
Tap W
Future Oncol; 2020 Sep; 16(25):1875-1878. PubMed ID: 32755241
[TBL] [Abstract][Full Text] [Related]
12. Effect of Mild and Moderate Hepatic Impairment (Defined by Child-Pugh Classification and National Cancer Institute Organ Dysfunction Working Group Criteria) on Pexidartinib Pharmacokinetics.
Zahir H; Greenberg J; Hsu C; Marbury TC; Lasseter KC; Xu LA; Tap WD; Healey JH; Stacchiotti S; LaCreta F
J Clin Pharmacol; 2022 Aug; 62(8):992-1005. PubMed ID: 35247274
[TBL] [Abstract][Full Text] [Related]
13. Pexidartinib: first approved systemic therapy for patients with tenosynovial giant cell tumor.
Gelderblom H; de Sande MV
Future Oncol; 2020 Oct; 16(29):2345-2356. PubMed ID: 32700568
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of Potential Drug-Drug Interaction Risk of Pexidartinib With Substrates of Cytochrome P450 and P-Glycoprotein.
Zahir H; Kobayashi F; Zamora C; Gajee R; Gordon MS; Babiker HM; Wang Q; Greenberg J; Wagner AJ
J Clin Pharmacol; 2021 Mar; 61(3):298-306. PubMed ID: 32918831
[TBL] [Abstract][Full Text] [Related]
15. The impact of calories and fat content of meals on oral ziprasidone absorption: a randomized, open-label, crossover trial.
Gandelman K; Alderman JA; Glue P; Lombardo I; LaBadie RR; Versavel M; Preskorn SH
J Clin Psychiatry; 2009 Jan; 70(1):58-62. PubMed ID: 19026256
[TBL] [Abstract][Full Text] [Related]
16. Pexidartinib Provides Modest Pain Relief in Patients With Tenosynovial Giant Cell Tumor: Results From ENLIVEN.
Healey JH; Tap WD; Gelhorn HL; Ye X; Speck RM; Palmerini E; Stacchiotti S; Desai J; Wagner AJ; Alcindor T; Ganjoo K; Martín-Broto J; Wang Q; Shuster D; Gelderblom H; van de Sande M
Clin Orthop Relat Res; 2023 Jan; 481(1):107-116. PubMed ID: 36001000
[TBL] [Abstract][Full Text] [Related]
17. Pexidartinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor: safety and efficacy.
Palmerini E; Longhi A; Donati DM; Staals EL
Expert Rev Anticancer Ther; 2020 Jun; 20(6):441-445. PubMed ID: 32297819
[TBL] [Abstract][Full Text] [Related]
18. Development of UPLC-MS/MS method for studying the pharmacokinetic interactions of pexidartinib with antifungal drugs in rats.
Shi L; Jiang Z; Zhang B; Tang C; Xu RA
J Pharm Biomed Anal; 2020 Sep; 188():113386. PubMed ID: 32502954
[TBL] [Abstract][Full Text] [Related]
19. Pexidartinib improves physical functioning and stiffness in patients with tenosynovial giant cell tumor: results from the ENLIVEN randomized clinical trial.
Van De Sande M; Tap WD; Gelhorn HL; Ye X; Speck RM; Palmerini E; Stacchiotti S; Desai J; Wagner AJ; Alcindor T; Ganjoo K; Martín-Broto J; Wang Q; Shuster D; Gelderblom H; Healey JH
Acta Orthop; 2021 Aug; 92(4):493-499. PubMed ID: 33977825
[TBL] [Abstract][Full Text] [Related]
20. Pexidartinib for the treatment of adult symptomatic patients with tenosynovial giant cell tumors.
Baldi GG; Gronchi A; Stacchiotti S
Expert Rev Clin Pharmacol; 2020 Jun; 13(6):571-576. PubMed ID: 32478598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]